Blood test guides next move in lung cancer fight
NCT ID NCT07375316
Summary
This study is for people with advanced non-small cell lung cancer who have a specific genetic change (EGFR mutation). It tests if adding a second drug (sacituzumab tirumotecan) to their current medication (osimertinib) helps control the cancer better. The decision to add the second drug is based on a blood test that looks for tiny pieces of cancer DNA. About 120 people will take part to see if this personalized approach is safe and effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences
RECRUITINGMeizhou, Guangdong, 514031, China
Contact
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
Contact
-
The First Affiliated Hospital of Shantou University Medical College
RECRUITINGShantou, Guangdong, 515041, China
Conditions
Explore the condition pages connected to this study.